Sponsor Pipeline

argenx Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
34
Active Trials
20
Recruiting
14
Phase 3
4
Disease Areas
8
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-02 NCT06078553
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to…
Trial sites expanded: 23 -> 30 locations
2026-06-02 NCT07284420
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to…
Trial sites expanded: 10 -> 13 locations
2026-06-02 NCT07294170
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy…
Trial sites expanded: 10 -> 15 locations
2026-05-29 NCT07091630
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Trial sites expanded: 43 -> 56 locations
2026-05-28 NCT06078553
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to…
Trial sites expanded: 20 -> 23 locations
2026-05-21 NCT06742190
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With…
overall status: "Recruiting" → "Active Not Recruiting"
2026-05-21 NCT06742190
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With…
Primary endpoint(s) modified
2026-05-21 NCT06742190
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With…
Enrollment increased: 115 -> 154 participants
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-10 NCT07638566 A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent… Phase 2/3 Not Yet Recruiting
2026-05-28 NCT07610564 A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults… Phase 1 Not Yet Recruiting
2026-05-28 NCT07612020 A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an… Phase 1 Recruiting
2026-05-19 NCT07595653 A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People… Recruiting
2026-05-19 NCT07596849 A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants… Phase 3 Not Yet Recruiting
Active Trials by Phase
Phase 4
1
Phase 3
9
Phase 2/3
5
Phase 2
8
Phase 1
4
Not specified
7
Active Trials — top 25 of 34
NCT IDTitleConditionStatus
Phase 4
NCT06909214 A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With… New Onset Generalized Myasthenia Gravis (gMG) Recruiting
Phase 3
NCT06544499 A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With… Primary Immune Thrombocytopenia (ITP) Recruiting
NCT06920004 A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP Chronic Inflammatory Demyelinating Polyneuropathy Recruiting
NCT07091630 A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP Chronic Inflammatory Demyelinating Polyneuropathy Recruiting
NCT04812925 A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in… Primary Immune Thrombocytopenia Active, Not Recruiting
NCT06684847 A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's… Primary Sjogrens Disease Active, Not Recruiting
NCT07570316 A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants… Graves' Disease Not Yet Recruiting
NCT07596849 A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants… Graves Disease Not Yet Recruiting
NCT06742190 A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With… Multifocal Motor Neuropathy (MMN) Active, Not Recruiting
NCT05979441 A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of… Myositis Enrolling by Invitation
Phase 2/3
NCT04833894 Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod… Generalized Myasthenia Gravis Recruiting
NCT07194850 A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age… Immune Thrombocytopenia (ITP) Recruiting
NCT06392386 A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With… Generalized Myasthenia Gravis Recruiting
NCT05374590 Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod… Generalized Myasthenia Gravis Enrolling by Invitation
NCT07638566 A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent… Chronic Inflammatory Demyelinating Polyradiculoneuropathy Not Yet Recruiting
Phase 2
NCT06503731 A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by… Antibody-mediated Rejection Recruiting
NCT06655155 A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic… Systemic Sclerosis (SSc) Recruiting
NCT07287982 A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and… Spinal Muscular Atrophy (SMA) Recruiting
NCT07284420 ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to… AChR-Ab Seropositive Generalized Myasthenia Gravis Recruiting
NCT05405361 A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy… Multifocal Motor Neuropathy (MMN) Active, Not Recruiting
NCT05907096 ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function Delayed Graft Function Active, Not Recruiting
NCT06441682 A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral… Amyotrophic Lateral Sclerosis Active, Not Recruiting
NCT07583641 A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune… Autoimmune Encephalitis (AE) Not Yet Recruiting
Phase 1
NCT07377396 A Study to Assess the Safety of ARGX-124 in Healthy Volunteers Healthy Volunteers Recruiting
NCT06436742 A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants… Congenital Myasthenic Syndrome Recruiting
View all 34 active argenx trials with filters →
Disease Areas
Get alerts when argenx's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free